In This Article:
-
Group Revenue: EUR200 million, a 4% decrease versus Q1 2024.
-
Shared R&D Revenue: EUR140.6 million, down from EUR155.2 million in Q1 2024.
-
Just Evotec Biologics Revenue: EUR59.4 million, showing strong growth.
-
Adjusted Group EBITDA: EUR3.1 million.
-
Operating Cash Flow: Improved versus prior year due to favorable changes in working capital.
-
CapEx Spending: EUR18 million in Q1 2025, a reduction from Q1 2024.
-
Liquidity: Decreased by EUR26 million to EUR371 million by end of March 2025.
-
Net Debt: Increased to EUR107 million, with a net debt leverage of 5.97 times adjusted.
-
Full Year 2025 Guidance: Group revenues of EUR840 million to EUR880 million, R&D expenditure of EUR40 million to EUR50 million, and adjusted EBITDA of EUR30 million to EUR50 million.
Release Date: May 06, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Evotec SE (NASDAQ:EVO) has made significant progress in its protein degradation collaboration with BMS, showcasing its strategy of technology leadership.
-
The company received a grant from the Korean government to develop novel antibody treatments for lung fibrosis, highlighting its capabilities in drug discovery.
-
Just Evotec Biologics delivered strong growth in Q1 2025, with revenues slightly ahead of expectations.
-
Evotec SE (NASDAQ:EVO) is leveraging cutting-edge technology and AI-driven innovation to accelerate drug discovery and improve success probabilities.
-
The company has implemented significant cost-saving measures, including site closures and headcount reductions, which are expected to positively impact future financials.
Negative Points
-
Evotec SE (NASDAQ:EVO) experienced a 4% decrease in group revenues in Q1 2025 compared to Q1 2024, primarily due to a decline in shared R&D revenue.
-
The market for shared R&D remains soft, resulting in revenue decline and performance slightly below expectations.
-
The company faces temporary lower BMS revenue, which is expected to continue in the midterm.
-
Evotec SE (NASDAQ:EVO) has a temporarily elevated net debt leverage, with a net debt of EUR107 million.
-
The company is operating in a cautious market environment with conservative spending from clients, impacting revenue growth.
Q & A Highlights
Q: Given the deviation in segment performance, with shared R&D underperforming and Just Evotec Biologics (JEB) overperforming, do you expect this trend to persist? Also, how might biotech and pharma layoffs impact your CRO activities? A: (Christian Wojczewski Wojczewski, CEO) The guidance remains unchanged as the overall revenue is balanced by the performance of both segments. The shared R&D market remains soft, but we are confident in our guidance. Layoffs in biotech and pharma could lead to more CRO activities as companies outsource work.